Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amy Goldstein; Jerry Vockley, MD, PhD
• Collaborator: Ultragenyx Pharmaceutical Inc

Criteria

Inclusion Criteria:

• This treatment plan is intended for the use of UX007 (triheptanoin) in the treatment of a single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome.

Exclusion Criteria:

• Not applicable as study only includes one patient.